May. 8, 2014, 4:35 PM| Comment!
Mar. 14, 2014, 12:48 PM
Mar. 13, 2014, 5:42 PM
Mar. 13, 2014, 5:02 PM| Comment!
Feb. 20, 2014, 12:47 PM
Feb. 20, 2014, 11:28 AM
- "Procysbi should become an important alternative for treating patients with nephropathic cystinosis," writes analyst William Tanner reiterating his Outperform and $17 price target. "The pace of market uptake has somewhat debunked the notion that the cost of therapy would adversely position the drug vs. Cystagon."
- Today's "encouraging" data on RP103 for Huntington's Disease, may also include evidence the drug could be "effective for treating a broad range of conditions characterized by mitochondrial disorders and intracellular cystine accumulation."
- RPTP +13.4%
Feb. 20, 2014, 9:11 AM
Feb. 20, 2014, 7:29 AM| Comment!
Jan. 10, 2014, 9:13 AM| 8 Comments
Jan. 10, 2014, 8:54 AM
- Add Raptor Pharmaceuticals (RPTP) to the list of stocks benefiting from the rally in liver disease plays sparked Thursday by ICPT.
- The company — which is developing RP103 for NAFLD — saw its shares rise 6% yesterday, and early trading suggests today will be another positive session.
- RPTP +7.5% premarket
- See also: GALT, CNAT piggyback on ICPT NASH results
Dec. 16, 2013, 4:40 PM
- It's been a rough couple of sessions for Raptor Pharmaceuticals (RPTP) as the shares are off some 9.5% since last Thursday (although still up ~116% YTD).
- The company could have done without comments out of Favus, where analysts have reportedly called Procysbi "a situation akin to Acthar Gel, with one major difference: The availability of a substantially cheaper version (Cystagon) of the exact same drug [where the] only difference is dosing frequency."
- Also mentioned is UnitedHealth's supposed move to put Procysbi on 2014's excluded drug list.
- Summing up, Favus has a question for RPTP investors: "At what price would QCOR trade if a generic version of Acthar Gel was available at a 96% discount?" The firm calls the similarities between RPTP and QCOR "striking."
Oct. 30, 2013, 8:34 AM
- Alkermes (ALKS) started at Market Perform. Price target is $31.
- Sarepta Therapeutics (SRPT) started at Market Perform. Price target is $48.
- Regulus Therapeutics (RGLS) started at Outperform. Price target is $15.
- Forest Labs (FRX) started at Market Perform. Price target is $48.
- Supernus Pharmaceuticals (SUPN) started at Outperform. Price target is $12.
- Raptor Pharmaceuticals (RPTP) started at Outperform. Price target is $17.
- Kythera Biopharmaceuticals (KYTH) started at Outperform. Price target is $58.
- Endo Pharmaceuticals (ENDP) started at Market Perform. Price target is $40.
- Valeant Pharmaceuticals (VRX) started at Outperform. Price target is $130.
- Aegerion Pharmaceuticals (AEGR) started at Outperform. Price target is $105.
Sep. 27, 2013, 5:37 PM
Sep. 25, 2013, 9:37 AM
- Raptor Pharmaceuticals (RPTP) falls in early trading on the heels of an Oppenheimer downgrade.
- "We believe that the market is already pricing in Procysbi adoption by 80%+ patients in the US and EU at current valuation," analyst Boris Peaker says, removing his $11 price target.
- Oppenheimer also says success in Huntington's (RP103) is critical for RPTP — "we view [this] as very risky," Peaker notes.
- Another concern: Procysbi pricing in Europe as "reimbursement may be more challenging" than in the U.S. See: Procysbi gets EU marketing authorization.
Sep. 12, 2013, 11:02 AM
- It's "sell the news" time for Raptor Pharmaceuticals (RPTP -0.9%) apparently, as the shares trade lower after the European Commission approves PROCYSBI as an orphan medicinal product for the treatment of nephropathic cystinosis.
- The drug got a positive CHMP opinion back in June (which usually bodes well for an EC nod) and was approved by the FDA in April.
- The aforementioned orphan medicinal product designation gives PROCYSBI 10 years of market exclusivity. (PR)
Aug. 29, 2013, 9:56 AM
- Raptor Pharmaceutical (RPTP) drops 5.7% to $12.02 following a bearish piece on Seeking Alpha by Gravity Research, which has given the stock a price target of below $4 after initiating coverage.
- Gravity Research reckons that the most that Raptor can expect to generate from its flagship drug Procysbi, which the FDA recently approved for treating nephropathic cystinosis, is "less than $4/share even under ideal conditions"
- Gravity Research also "assigns zero value to Raptor's pipeline due to strong evidence that the fundamental theories behind its leading indications are flawed."
- Nephropathic cystinosis is a rare genetic disorder "that causes the amino acid cystine to accumulate in every cell of the body, leading to kidney problems and the loss of too much sugar, proteins, and salt through the urine." (Medscape)
RPTP vs. ETF Alternatives
Other News & PR